Neil Kumar - Mar 19, 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Chief Executive Officer, Director
Signature
/s/ Neil Kumar
Stock symbol
BBIO
Transactions as of
Mar 19, 2025
Transactions value $
$0
Form type
4
Date filed
3/21/2025, 06:09 PM
Previous filing
Feb 27, 2025
Next filing
Mar 27, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (Right to Buy) Award $0 +71.2K $0.00 71.2K Mar 19, 2025 Common Stock 71.2K $33.75 Direct F1
transaction BBIO Restricted Stock Units Award $0 +185K $0.00 185K Mar 19, 2025 Common Stock 185K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/16th of the shares subject to this option vest and become exercisable on May 16, 2025, and thereafter, 1/16th of the shares subject to this option will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3 The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2025, and thereafter, 1/16th of the underlying shares will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.